June 2nd 2025
“Higher pretreatment HER2 amplicon mRNA signature and HER2 protein expression predicted improved outcomes with T-DXd for [metastatic breast cancer],” Paolo Tarantino, MD, PhD, said.
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances
View More
Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer
View More
Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials
View More
Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care
View More
Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care
View More
Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
Lower Breast Cancer Mortality Seen With Estrogen Use
April 1st 1996SAN FRANCISCO--Use of estrogen supplements may lower breast cancer mortality, an American Cancer Society study has shown. The study, which was discussed at the ACS's science writers meeting, followed 400,000 women who provided data about their cancer risk factors. After 9 years, breast cancer mortality was 16% lower in those women who used estrogen, suggesting that their tumors were less aggressive.
OC Use May Favorably Influence Breast Cancer Survival
April 1st 1996Although most studies of the relationship between oral contraceptives (OCs) and breast cancer have focused on a possible causative role for OCs, new data suggest that breast cancer patients with a history of OC use may actually fare better than women who have never taken the pill.
The "Epidemic" of Breast Cancer in the U.S.--Determining the Factors
April 1st 1996It is widely accepted that the causation of cancer is the result of environmental exposures (including endogenous hormone exposure) and genetic susceptibility. Ultimately, to prevent breast cancer, we must understand both the environmental and genetic components.
The "Epidemic" of Breast Cancer in the U.S.--Determining the Factors
April 1st 1996It is perhaps not surprising that the increased incidence of a disease that has a major impact on mortality in young women (even though the absolute risk of death from breast cancer in this age group is low) should create so much interest. Yet, despite decades of research, it is by no means clear that everyone would agree with King and Schottenfeld that the appropriate approach to breast cancer prevention is one that "focuses on the physiologic effects of the sex steroid hormones and their potential interactions with family history." However, this tantalizing statement appearing at the end of the abstract of their article fortunately is elaborated upon at the end of the article itself. This elaboration refers specifically to physical activity, energy consumption, obesity, pregnancy history and exogenous estrogens and their potential interactions with family history, with which many will agree.
Final Word on Diet-Breast Cancer Link Must Come From Clinical Trials: WHI
March 1st 1996BETHESDA, Md--Concerned that a New England Journal of Medicine article reporting no link between fat intake and breast cancer might deter women from joining the diet-cancer segment of the NIH-sponsored Women's Health Initiative (WHI), its top leaders took an unusual step.
LHRH Agonist Matches Ovariectomy Results: SWOG
March 1st 1996PARIS--The luteinizing hormone-releasing hormone (LHRH) agonist goserelin (Zoladex) proved as effective as surgical ovariectomy in premenopausal women with estrogen and/or progestogen receptor-positive metastatic breast cancer, a randomized multicenter study has shown.
DaunoXome Shows Promise as Breast Cancer Treatment
March 1st 1996Data presented at the 18th Annual San Antonio Breast Cancer Symposium in Boulder, Colorado, shows that moderate-dose DaunoXome, NeXstar Pharmaceuticals' liposomal formulation of daunorubicin, is well-tolerated and has promising efficacy in treating advanced breast cancer. Moreover, the limited toxicity observed in this trial, particularly the absence of cardiotoxicity, suggests that DaunoXome may be useful in ameliorating the side effects that accompany high-dose anthracycline-based chemotherapy for metastatic breast cancer. The data, generated in a phase II study funded by NeXstar, were presented by P.S. Hupperets, MD, of the Akademisch Ziekenhuis, in Maastricht, The Netherlands.
Dr. Vogel to Lead Joint Breast Cancer Program
March 1st 1996PITTSBURGH--Victor Vogel, MD, MHS, will lead a newly established joint breast cancer program of the University of Pittsburgh Cancer Institute and Magee-Womens Hospital. He will also join the University of Pittsburgh as professor of medicine and epidemiology.
Experts Review NCI Recommendation to Limit Tamoxifen Duration to Five Years
March 1st 1996An expert panel of seven cancer researchers and a representative of the National Alliance of Breast Cancer Organizations (NABCO) came together at the San Antonio Breast Cancer Symposium for a roundtable discussion of the use of tamoxifen (Nolvadex), sponsored by PRR, Inc., publisher of Oncology News International and the journal ONCOLOGY.
Should We Recommend Screening Mammography for Women Aged 40 to 49?
March 1st 1996In clinical trials, screening mammography has been shown to reduce mortality from breast cancer by about 25% to 30% among women aged 50 years and older after only 5 to 6 years from the initiation of screening. Among women 40 to 49 years old, the evidence supporting the efficacy of screening mammography is less convincing.
No Adverse Effects of HRT on Breast Cancer Prognosis Seen
March 1st 1996SAN ANTONIO--Three studies reported at the San Antonio Breast Cancer Symposium show no apparent adverse effects of hormone replacement therapy (HRT) on breast cancer and, in fact, suggest that breast cancers in patients with a history of HRT may have a more favorable prognosis in terms of histologic grade and estrogen-receptor (ER) levels.
NSABP to Study Docetaxel in Operable Breast Cancer
February 1st 1996COLLEGEVILLE, Penn--Rhône-Poulenc Rorer Inc. and the National Surgical Adjuvant Breast and Bowel Project (NSABP) have announced the initiation of a new clinical trial (B-27) utilizing docetaxel (Taxotere) in women with operable breast cancer.
Expert Panel Dispels Misinformation About Tamoxifen
February 1st 1996An expert panel of seven cancer researchers and a patient advocate came together at the San Antonio Breast Cancer Symposium for a roundtable discussion on tamoxifen (Nolvadex), sponsored by PRR, Inc., publisher of Oncology News International and the journal ONCOLOGY.
Angiogenesis Precedes Breast Cancer Development, Van Nuys Study Shows
February 1st 1996SAN ANTONIO--Mammographic signs of angiogenesis and neovascularity may identify a developing breast cancer years before the lesion becomes visible, Parvis Gamagami, MD, said at the San Antonio Breast Cancer symposium.
Breast Cancer Prevention Strategies
February 1st 1996In this issue, Love and Vogel bring attention to the fact that most breast cancers are not inherited but are the result of several, varied hormonal influences. This is an important message because prevention of breast cancer for some women can be accomplished by hormone manipulation from moderate exercise, maintaining low body mass, abstention from alcohol, and lactation. The authors discuss the physiologic role of delayed pregnancy but avoid the issue in terms of preventive strategy. Many women choose to delay pregnancy in pursuit of career development for economic reasons. This makes for a difficult choice in terms of breast cancer risk, but one that should be addressed. The article proposes that lobular maturation and exposure of the breast to hormones are two key processes in breast cancer. Indeed, emerging data also suggest that excess hormonal exposure in utero may influence adult breast cancer risk.
Preop 5-FU May Avoid Mastectomy in High Risk Early Breast Ca
February 1st 1996NEW YORK--Women facing mastectomy because of high-risk early breast cancer may benefit from a new strategy that reduces tumor size, allowing conservative surgery or eliminating the need for surgery, Ian E. Smith, MD, said at the symposium of the Chemotherapy Foundation.
Breast Cancer Info Now on Internet
January 1st 1996NEW YORK--Women seeking information about breast cancer can now turn to their computers. The National Alliance of Breast Cancer Organizations (NABCO) has established the first nonprofit organization breast cancer web site (http://www.nabco.org) to provide In-ternet users with up-to-date information about the latest research, current treatment options, support services, and links to other Internet sites.
Monica Morrow on the Pros and Cons of Stereotactic Breast Biopsy
January 1st 1996Developed as a way to sample mammographic abnormalities in a potentially less invasive way, stereotactic technology has generated significant controversy. Speaking at the 11th International Breast Cancer Meeting in San Antonio earlier this year,
Limits on Tamoxifen Duration Questioned
January 1st 1996SAN ANTONIO--The NCI's clinical alert advising physicians to limit the use of tamoxifen (Nolva-dex) in early breast cancer to no more than 5 years may be a "premature judgment" that was based on a randomized trial of insufficient size, Prof. Richard Peto, of the University of Oxford's ICRF Clinical Trial Service Unit, said at the San Antonio Breast Cancer Symposium.
Difficulties in Translating Relative Risks Into Absolute Risk
January 1st 1996PARIS--When counseling women about breast cancer risk, physicians face the difficulty of translating relative risks into real-life prospects, Michael Baum, CHM, FRCS, of the Royal Marsden Hospital, London, said in a presentation at the Eighth Annual European Cancer Conference (ECCO-8).
Zoladex Gets Indication for Advanced Breast Ca
January 1st 1996WILMINGTON, Del--Zoladex (goserelin acetate implant), Zeneca Pharmaceuticals' gonadotropin-releasing-hormone (GnRH) agonist, has received approval for use in the treatment of advanced breast cancer in premenopausal and perimenopausal women.